Heusden-Zolder, Belgium, 2^nd March 2021 – Rejuvenate Biomed NV ("Rejuvenate"), a biomedical company developing prescription drugs for age-related diseases, announces it has completed a EUR 3.2 million Series A round.

Munich, Germany, March 1^st 2021 – CatalYm GmbH, Announces Key Management and Board Changes:

• Dr. Manfred Ruediger steps down as Chief Executive Officer of CatalYm
• Dr. John Haurum succeeds Dr. Holger Reithinger as Chairman of the Supervisory Board

NEW YORK, 2021 – SWORD Health, the world's fastest growing virtual musculoskeletal (MSK) care provider, has raised a $25 million financing round, bringing SWORD's cumulative fundraising to $50 million. The round was led by Todd Cozzens, Managing Partner at Transformation Capital and former healthcare investor at Sequoia Capital.

Munich, Germany, January 28^th, 2021 – CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, announced today the start of clinical development of CTL-002, its proprietary GDF-15 neutralizing antibody designed to enhance effector T cell entry into the tumor microenvironment.

Gosselies, 27th November 2020 – Already celebrated by Deloitte's Technology Fast50 in 2015 and 2018, OncoDNA is thrilled to announce that it has received this year's award in the biotechnology and pharmaceutical category.

On November 24^th 2020, 21 winners of the Computable Awards 2020 were announced during a live broadcast in the Scala Theater at Jaarbeurs in Utrecht. For the first time, this year also included the Dutch Applied AI Award, in collaboration with Podcast "De Dataloog" and the Amsterdam University of Applied Science (HvA). Our very own Katinka de Korte was invited as a guest and found herself happily surprised when she was handed this brand new award for DEARhealth!

Munich, Germany, November 10^th, 2020: CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the closing of its EUR50 million Series B financing round.

Five years ago, this publication told you about DEARhealth, a health care platform from UCLA that grew into a business. A lot has happened in the past five years: The digital health company, founded by Drs. Daniel Hommes and Eric Esrailian, UCLA professors of medicine, offers a provider platform and patient app that helps manage chronic conditions, improve patient outcomes, and lower associated health costs.

Hamburg, October 19^th, 2020: Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural immune tolerance induction capabilities of the liver, today announced the successful closing of a €22 million (~$26 million) Series B financing round. New investors Vesalius BioCapital III and BioMedPartners co-led this transaction, which included participation from all of Topas' existing investors.

Hamburg, October 19^th, 2020: Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural immune tolerance induction capabilities of the liver, today announced the appointment of Klaus Martin, Ph.D., as Chief Executive Officer.